Thoracic Cancer Research - Penn State Cancer Institute
Thoracic Cancer Research
Research into thoracic cancer at Penn State Cancer Institute is conducted by our dedicated thoracic cancer team. See current clinical trials and members of that team here.
Clinical Trials
Repository of Lung Cancer Diagnostic Procedure Images
Phase II Study of Osimertinib in Advanced NSCLC Patients with Exon 20 Mutations in EGFR
The COVID-19 and Cancer Consortium (CCC19) Registry
A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153
NRG-LU007 Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial
Psychosocial Challenges and Educational/Occupational Aspirations of Adolescent/Young Adult Cancer Survivors
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without Radiation Therapy for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
NRG-LU008: Phase III Prospective Randomized Trial Of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed By Concurrent Mediastinal Chemoradiation For Locally Advanced Non-Small Cell Lung Cancer
A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery
Consolidative Use Of Radiotherapy To Block (Curb2) Oligoprogression In Patients With Metastatic Non-Small-Cell Lung Cancer - A Randomized Phase 3 Trial (BR.38)
EA5221: A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable older adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
General Protocol for the Acquisition of Whole Blood for the Detection and Characterization of Circulating Tumor Cells and/or Tumor Specific Immunity/Immune Cell Activation for any Malignancy at any Stage of Disease
Disease Team Members
| First Name | Last Name | Title | Role | ||
|---|---|---|---|---|---|
 |
Mitchell | Machtay | MD | ||
 |
Michael F. | Reed | MD | ||
 |
Matthew D. | Taylor | MD | ||
 |
Jennifer | Toth | MD | ||
 |
Leonard | Tuanquin | MD |
Research into thoracic cancer at Penn State Cancer Institute is conducted by our dedicated thoracic cancer team. See current clinical trials and members of that team here.
Repository of Lung Cancer Diagnostic Procedure Images
Phase II Study of Osimertinib in Advanced NSCLC Patients with Exon 20 Mutations in EGFR
The COVID-19 and Cancer Consortium (CCC19) Registry
A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153
NRG-LU007 Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial
Psychosocial Challenges and Educational/Occupational Aspirations of Adolescent/Young Adult Cancer Survivors
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without Radiation Therapy for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
NRG-LU008: Phase III Prospective Randomized Trial Of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed By Concurrent Mediastinal Chemoradiation For Locally Advanced Non-Small Cell Lung Cancer
A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery
Consolidative Use Of Radiotherapy To Block (Curb2) Oligoprogression In Patients With Metastatic Non-Small-Cell Lung Cancer - A Randomized Phase 3 Trial (BR.38)
EA5221: A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable older adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
General Protocol for the Acquisition of Whole Blood for the Detection and Characterization of Circulating Tumor Cells and/or Tumor Specific Immunity/Immune Cell Activation for any Malignancy at any Stage of Disease
| First Name | Last Name | Title | Role | ||
|---|---|---|---|---|---|
|
Mitchell | Machtay | MD | ||
|
Michael F. | Reed | MD | ||
|
Matthew D. | Taylor | MD | ||
|
Jennifer | Toth | MD | ||
|
Leonard | Tuanquin | MD |